Topic: Diary Marker

We are pleased to announce that Dr. Frank Borriello, Founder and CEO of Alloplex Biotherapeutics, will be presenting at the upcoming World Oncology Cell Therapy Congress, being held in Boston, MA, on April 25 & 26, 2023. The presentation will include emerging data from the SUPLEXA-101 clini...

Alloplex’s Founder and CEO, Dr. Frank Borriello, will be speaking at the 3rd Gamma Delta T Therapies Summit on Thursday 28th July 2022 at 11 AM in a session titled “Reviewing the clinical safety and efficacy of gamma delta therapies” on the Response in Solid Tumors of Non-Engineered Autologous Multi-Cell Therapy.

Alloplex’s Abstract (3599) ‘Interleukin-10 and transforming growth factor-beta do not suppress tumor killing activity of PBMC-derived SUPLEXA cells’ has been accepted by AACR and is scheduled for presentation in a Poster session at the 2022 Annual Meeting. We look forward to attending this year’s meeting in New...

Dr. Frank Borriello will be participating in Roth’s Capital Partners’ Virtual Healthcare Private Company Forum on June 28 as part of Cancer Panel 2: entitled Natural Killer Cell Approaches to Eradicate Tumors where he will be highlighting the differentiation of the Alloplex approach in the oncology cellular therapy...

The Innate Killer Cell Conference on March 24-25, 2021 held by Hanson Wade.

Alloplex CEO Frank Borriello MD, PhD will be presenting a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners on August 4 and 5, 2020.